taken from the original pathological evaluations following biopsies. Vascular sclerosis: 0 = normal; 1 = mild; 2 = moderate; 3 = severe. Lumen cells and lumen thrombi: 0 = normal; 1 = increased. Mesangial matrix: 0 = normal; 1 = focal; 2 = increased, mild; 3 = increased, nodular. Bowman's capsule thickening: 0 = normal; 1 = focal; 2 = circumferential. Interstitial fi brosis: 0 = no infl ammation; 1 = mild; 2 = severe.
Clinical information about the diabetic patients and controls was collected from the patients' fi les. The glomerular fi ltration rate (eGFR) was estimated using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula ( 29, 30 ) . Twentyfour hour urine albumin, protein, and creatinine were available to all patients in the last month prior to biopsy. Data on blood pressure were collected from the patients' fi les on the day of hospitalization for kidney biopsy.
As a control group (n = 12), we used diagnostic kidney biopsies from living kidney donors (n = 6) and nonaffected parts of tumor nephrectomy samples (n = 6). Control subjects were defi ned as having an eGFR >60 (ml/min) and <10% glomerulosclerosis and tubulointerstitial fi brosis.
Serum creatinine levels and albuminuria of the patients are presented in Table 1 . We grouped the cases according to CKD and rate of eGFR deterioration. Rate of progression was calculated from average rate of eGFR change per month following biopsy until initiation of dialysis or initiation of data collection. All patients were followed up in our department and have all clinical data in our patient fi les.
Electron microscopy
Kidney biopsy tissue was immediately fi xed in Karnovsky's fi xative and then 1% buffered osmium tetroxide (method that preserved lipids). The sample was dehydrated in a graded Dysregulation of PPAR activity is a potential cause of metabolic syndrome-related disorders, such as insulin resistance and hyperlipidemia. PPAR ␣ and PPAR ␦ regulate expression of genes involved in ␤ -oxidation of FAs. PPAR ␣ defi ciency has been shown to accelerate dyslipidemia, proteinuria, and renal failure in animal models with DN ( 16, 22 ) .
There is growing evidence that dysregulation of sterol regulatory element binding proteins (SREBPs) contributes to the pathogenesis of DN ( 23 ) . SREBPs serve as the master regulators of cellular FA and cholesterol synthesis; SREBP-1 regulates FA synthesis, whereas SREBP-2 regulates cholesterol synthesis ( 14 ) . In addition, the carbohydrate-responsive element binding protein (ChREBP) regulates the expression of ACC and FAS, and also regulates lipogenesis by induction of the glycolytic enzyme L-pyruvate kinase (L-PK) ( 24 ) .
Dysregulation of cholesterol metabolism has also been linked to lipotoxicity and lipid accumulation in diabetes. Cholesterol infl ux into cells is mediated by several independent receptors, including scavenger receptor class A (SR-A1), class B (CD36), lectin-like oxLDL receptor-1 (LOX-1 or OLR-1) ( 25 ) , and LDL receptor (LDLR) ( 15 ) . Cholesterol effl ux that prevents cholesterol accumulation is primarily mediated by ATP-binding cassette transporters (ABCA1 and ABCG1). Renal lipoprotein receptor expression correlates with kidney damage ( 26, 27 ) .
The aim of this study was to test whether renal dysfunction in human DN is associated with renal lipid accumulation, lipotoxicity, and dysregulation of renal FA and cholesterol metabolism.
MATERIALS AND METHODS

Kidney biopsy case selection and histological assessment
The study was approved by the Institutional Ethics Committee. Kidney samples were obtained from leftover portions of diagnostic kidney biopsies of patients with DN (n = 34) and normal kidneys (n = 12) from the pathological archives of the Department of Pathology at Rabin Medical Center.
All patients had T2D . DN was histologically confi rmed by hematoxylin and eosin, periodic acid-schiff, Masson's trichrome staining, immunofl uorescence microscopy for immunoglobulin, and complement and electron microscopy (EM) analysis.
Criteria for DN included glomerular hypertrophy, diffuse mesangial and focal nodular glomerulosclerosis, arteriolar hyalinosis, focal and segmental glomerulosclerosis, the presence of hyaline drops between Bowman's capsule and epithelial cells, and interstitial fi brosis ( 28 ) .
In the DN group, renal biopsy was performed according to clinical indications and in order to exclude the coexistence of other types of kidney disease due the presence of atypical features, including short duration between the diagnosis of diabetes and the onset of nephropathy and/or the absence of concomitant diabetic retinopathy. Cases were defi ned by the presence of diabetic histological changes consistent with DN and the absence of other potential causes of glomerulonephritis in the pathology evaluation.
The degrees of sclerosis, thickening, and fi brosis were evaluated on the basis of an arbitrary scale (0 = normal = 0%, 1 = mild = 20%, 2 = moderate = 20-40%, and 3 = severe = >40%) and were 
Lipid staining
4,4-Difluoro-1,3,5,7,8-pentamethyl-4-Bora-3a,4a-diaza-s -indacene (BODIPY) staining (which stains neutral lipids) was performed on 4 m-thick sections of fi xed frozen kidney DN biopsies and on leftover frozen tissue designated for immunofl uorescent microscopy. BODIPY (Molecular Probes, Invitrogen) was diluted in DMSO at a concentration of 1 mg/ml, applied to the kidney section in OCT for 30 min and costained with membranes using series of ethanol and embedded in an epoxy resin. Tissue was surveyed with a series of 1 m sections for a representative sample. The selected specimens were thin sectioned, viewed, and photographed with an electron microscope (transmission electron microscope, JEOL 1010) from the Rabin Medical Center pathology department. The sections were read by a nephropathologist to determine kidney morphology and lipid droplets (LDs). normal kidneys. Total RNA was isolated using RNAeasy mini columns (Qiagen, Valencia, CA). The manufacturer's protocol was followed with the exception of increased proteinase K digestion time. RNA quantity and quality were determined by optical density 260:280nm ratio on a NanoDrop spectrophotometer (NanoDrop Technologies, Wilmington, DE). RNA was converted to cDNA using RevertAid First Strand cDNA synthesis kit (Fermentas); cDNA was then amplifi ed using TaqMan PreAmp Master Mix (Applied Biosystems) for 14 cycles of preamplifi cation according to the manufacturer's protocol using target gene assays.
Candidate lipid and glucose metabolic gene expression were analyzed by real-time RT-PCR, performed as described previously ( 14 ), using the TaqMan and Syber system based on real-time detection of accumulated fl uorescence (ABI Prism Step One; Perkin-Elmer, Foster City, CA). Fluorescence for each cycle was quantitatively analyzed by an ABI Step One sequence detection system (PerkinElmer). In order to control for variation in the amount of DNA that was available for PCR in the different samples, gene expression of the target sequence was normalized in relation to the expression of an endogenous control, 18S rRNA or RPLPO (large ribosomal protein). Primer sequences and assay details are available upon request.
Statistical analysis
Values are shown as mean ± SEM unless otherwise specifi ed. Statistical analysis was performed using two-tailed Student's t -test for independent data. Pearson's correlations were calculated using GraphPad software. P < 0.05 was considered signifi cant. a fluorescein-labeled wheat germ agglutinin kit (Molecular Probes, Invitrogen).
Oil Red O staining was performed according to the manufacturer's protocol (Sigma) on 6 m-thick sections of fi xed frozen kidney tissue. The kidney sections were rinsed in distilled water, then in 60% isopropanol for 1 min, and stained for 15 min in the Oil Red O working solution (Sigma), then rinsed again for 1 min in 60% isopropanol and returned to distilled water. The slides were counterstained with hematoxylin for 1 min.
Filipin staining (which stains cholesterol) (125 g/ml; Sigma) was performed on 4 m-thick sections of fi xed frozen kidney under light-protected conditions for 2 h at room temperature.
Immunofl uorescence
Immunofl uorescence staining was performed on 4 m-thick sections of paraffi n-embedded human kidney biopsies. We used heatinduced epitope retrieval techniques (antigen-retrieval solution: citrate buffer, pH 6.0; Vector Laboratories). Kidney tissue images were obtained with a Leica TCS SP5 confocal microscope (Tel Aviv University). The adipophilin antibody used was anti-ADFP (AP125) (Fitzgerald ). Secondary antibodies were Alexa Fluor 488 tagged. Nuclei were stained with DAPI (Sigma). We used FITC-labeled wheat germ agglutinin (Vector Laboratories) for membrane staining.
Gene analysis
RNA was extracted from archives of formalin-fi xed paraffi nembedded tissue specimens of 34 DN kidney biopsies and 12 the diabetic group were older and consisted of a higher percentage of women, but these differences did not reach statistical signifi cance. Three control patients were diagnosed with T2D without renal involvement.
Histological evaluation showed severe glomerulosclerosis: global sclerosis of 34 ± 17% and segmental sclerosis of 20 ± 23%, tubular atrophy, interstitial fi brosis, vascular sclerosis, mesangial matrix expansion, and marked interstitial infl ammation.
The phenotype analysis represents all clinical and pathological diversity of DN from early CKD (CKD 1) to advanced CKD (CKD 4-5).
Patients with DN showed a progressive decline in kidney function with eGFR deterioration at a rate of 1.0 ± 0.9 ml/ min/1.73 m 2 /month (excluding patients who started dialysis in the 2 months after biopsy). Patients reached dialysis within 29.7 ± 23.6 months after kidney biopsy.
RESULTS
Clinical characteristics of the research participants
RNA samples were prepared from kidney biopsy samples from 34 DN patients and 12 normal controls. The clinical characteristics of the study participants are summarized in Table 1 . The DN patients had a higher prevalence of hypertension and obesity. DN patients were more likely to have dyslipidemia and to be on active statin (HMG-CoA reductase inhibitor) therapy. LDL levels were the same in both groups, but diabetics had higher levels of serum TGs. DN patients had decreased eGFR, increased proteinuria, hypoalbuminemia, and increased serum creatinine and urea. Patients in ( Fig. 2 ) . LDs are round membrane-coated organelles fi lled with inert lipids that can be well observed by EM in adipocytes and fatty liver. LDs in DN showed different electron densities depending on the type of lipid and were in different sizes. LDs appeared in clusters mostly seen in podocytes, both in the podocyte cell body and in the major foot processes. Some podocytes were loaded with LDs, while others had no lipid deposits.
Increased lipid staining in human kidney
We studied renal lipid accumulation by using different staining methods on six frozen DN kidney tissue biopsies: Oil Red O, BODIPY staining, and fi lipin staining ( Fig. 3A ) . We found marked neutral lipid accumulation in both glomeruli and tubulointerstitium, as determined by Oil Red O staining and by BODIPY staining in diabetic kidneys. We also found evidence for cholesterol accumulation by fi lipin staining ( Fig. 3 ) . In the absence of unfi xed normal frozen kidney samples and due to the fact that lipids dissolve during routine fi xation methods, we used immunostaining of adipophilin (ADRP), a LD-associated protein, to quantify LDs in fi xated processed tissue ( 16, 17 ) . ADRP staining ( Fig. 3 ) showed increased LD protein expression in DN compared with normal kidneys. Furthermore, ADRP (PLIN2) mRNA expression was increased in DN kidneys in the early stages of disease progression ( Fig. 3 ) .
Regulation of FA metabolism enzymes in the diabetic kidney
To determine the possible mechanism of the lipid accumulation in the kidney of the DN group, we measured the expression of several key genes involved in FA synthesis, catabolism, uptake, and oxidation in DN patients and compared them to normal controls ( Fig. 4 ) .
The DN group had increased SCD1 mRNA abundance, which was associated with increased TG content. In addition, there was increased FA transporter CD36 mRNA, indicative of increased FA uptake ( Fig. 4 ) .
Most of the lipogenic genes that we studied, including SREBP-1c, FAS, ACC, ChREBP, and L-PK were all decreased. In addition, expression of diacylglycerol O-acyltransferase 1 did not change. These results suggest that accumulation of TGs is not due to increased active synthesis in the stage of long-standing fi brotic diabetic kidney injury.
The most signifi cant changes were found in the expression of genes and enzymes that control FA oxidation. ACO1 and CPT1 were signifi cantly lower in the DN kidneys ( Fig. 4 ) . This was also associated with a signifi cant downregulation of PPAR ␣ and PPAR ␦ , the key transcriptional regulators of FA oxidation ( Fig. 4 ) . L-FABP (FA binding protein), which can be used as a biomarker in the urine of DN patients ( 33 ) and is a lipid-binding protein responsible for transporting FAs to intracellular sites of oxidation, was also downregulated. The expression of renal LPL mRNA, which hydrolyzes circulating TGs, was signifi cantly decreased in DN. Downregulation of renal LPL
Pathognomonic DN gene dysregulation
As expected in diabetic kidneys ( 31, 32 ) , there was increased expression of infl ammatory and fi brotic cytokines: TGF ␤ , TNF ␣ , and collagen. Podocyte marker genes were downregulated. Tubular sodium/glucose cotransporter 2 increased signifi cantly ( Fig. 1 ) with increased expression of the receptor for advanced glycation endproducts (RAGE).
Increased lipid deposits in human kidney
EM examination disclosed all the known features of DN, including podocyte process effacement, widening of glomerular basement membrane, and mesangial expansion. may increase TG levels in kidney tissue ( 34 ) . Angiopoietinlike protein 4 (Angptl4), which has recently been shown to play a major role in mediating hypertriglyceridemia in nephrotic syndrome ( 35 ) and also to inhibit LPL ( 36 ), was increased ( Fig. 4 ) .
Taken together, these data suggest that increased FA uptake and decreased FA oxidation may lead to TG and neutral lipid accumulation in the diabetic kidney. Furthermore, upregulation of lipoprotein receptors can also result in the increased delivery of TGs to the cell by uptake of TGs in VLDLs and chylomicron remnants.
Regulation of cholesterol metabolism enzymes in the diabetic kidney
To gain further insight into the mechanisms responsible for accumulation of cholesterol in the kidney, we analyzed proteins and enzymes involved in cholesterol synthesis, uptake, and effl ux.
The expression of LOX-1 (OLR-1) was very low in normal kidneys and signifi cantly upregulated in the diabetic kidneys. We also found upregulation of LDLR, acetylated LDLR-NR-A1, and CD36 (SR-BI), which is involved in the uptake of oxLDL, as well as TG uptake ( Fig. 5 ) . The expression of CXCL16, the main chemokine receptor in podocytes mediating uptake of oxLDL ( 37 ) , was decreased, possibly as part of decreases in the mRNA of all other podocyte markers ( Fig. 1 ) .
In DN, we also found decreased expression of the cholesterol effl ux genes: ATP-binding cassette transporters (ABCA1, ABCG1) and apoE ( Fig. 5 ) . The expression of liver X receptor ␣ ( 30, 38 ), the nuclear receptor which regulates these cholesterol effl ux genes, was also downregulated.
No signifi cant differences in HMG-CoA reductase and synthase or SREBP-2 mRNA levels were seen between the groups, suggesting no change in cholesterol synthesis ( Fig. 5 ) .
Taken together, these data suggest that increased cholesterol uptake and decreased cholesterol cellular effl ux may lead to cholesterol accumulation in the diabetic kidney. 
Correlation between lipid metabolic genes and renal dysfunction
To determine whether the accumulation of lipids within the kidney is associated with alterations in kidney function, we studied the correlation between eGFR, proteinuria, and genes of lipid metabolism. We found highly signifi cant correlations between increased expression of LDLR, oxLDL, acetylated LDL (acLDL) , and CD-36 versus the progression of DN and deterioration of eGFR. On the other hand, there was a highly signifi cant negative correlation between genes that regulate FA oxidation, including PPAR ␣ , ACO, CPT1, and eGFR. There was also a highly signifi cant correlation between decreased mRNA expression of genes that regulate cholesterol effl ux, ABCA1 and ABCG1, and eGFR and proteinuria ( Fig. 6 ; Tables 2, 3 ).
DISCUSSION
Ectopic lipid accumulation in the liver, heart, and pancreas is associated with lipotoxicity, infl ammation, and fibrosis. Although animal studies suggest that lipotoxicity also contributes to renal dysfunction, its importance for human DN has not been established. The aim of this work was to determine whether lipids accumulate in the human diabetic kidney and to elucidate the alterations in lipid metabolism that may be associated with lipotoxicity and deterioration of renal function (eGFR).
In this study, we showed that heavy lipid deposition is a common feature of human DN. These results are mostly consistent with the fi ndings in animal models of diabetic kidney in which accumulation of lipid, lipotoxicity, and lipid metabolism dysregulation are associated with renal damage ( 39 ) .
This phenomenon most likely has been previously underestimated, probably because diabetic patients rarely undergo renal biopsy once proteinuria and renal failure develop, and furthermore, lipids and cholesterol are not preserved in routine pathology tissue processing and in EM processing.
Development of a new technique to extract mRNA from pathology archives ( 40 ) and departmental policy to perform kidney biopsy on diabetic patients in order to reject other differential diagnoses allowed us to collect, over the years, a large group of DN biopsies that represent different stages of DN. By using a large number of biopsies, we overcame the within-subject biological variation and bias that result from choosing a selected group of patients for kidney biopsy. Using clinical data, eGFR, and the rate of renal progression, and correlating these data with gene expression, further helped us overcome the fact that we tend to perform biopsies when there is atypical presentation of DN: rapid kidney deterioration, severe proteinuria, short duration of diagnosed diabetic, or AKI events.
Kidney tissue can also be purchased from tissue banks, but the advantage of this work is that all the patients were followed-up and treated in our department before and after the biopsy until dialysis or transplantation. We have all clinical records and information on medication that are not available in tissue banks.
Lipids are not visible after normal processing of kidney biopsies for routine study. As seen in the case of cholesterol emboli, all lipids dissolved in the process of preparing biopsies.
LDs are cytosolic structures in which lipids are stored as a central core of TGs and cholesterol esters surrounded by LD-associated protein ( 25 ) . These organelles allow storage of potentially toxic TGs, which can then be broken down by LPL into FFAs for mitochondrial ␤ -oxidation to supply the cell with ATP ( 41 ). Staining for adipophilin (ADRP ), which is the protein component of LDs, is possible even in formalin embedded kidney tissue and can be used to quantify lipid accumulation.
A novel fi nding of our study was the demonstration of marked lipid accumulation in renal tissues from diabetic patients, as shown by different lipid staining methods including BODIPY, Oil Red O, fi lipin, and ADRP immunofl uorescence. Furthermore, we showed the presence of LDs by EM in glomerular and tubular cells. LDs can be seen in different stages of progression of DN kidneys and are mostly prominent in podocytes. We found upregulation of ADRP staining and Oil Red O staining in diabetic kidneys, when compared with normal kidneys. However, in advanced fi brotic kidneys the amount of LDs tends to decrease. This process may be similar to the disappearance of LDs in "burnt out" cirrhotic liver, secondary to 'non-alcoholic steatohepatitis (NASH ) ( 42 ) .
Different animal models for kidney disease, including metabolic syndrome ( 43 ) , chronic glomerulopathy, nephrotic syndrome ( 44 ) , chronic renal insuffi ciency, DN, obesity-associated renal disease, aging nephrosclerosis, and acute kidney injury ( 44 ) , also showed accumulation of lipids in the renal tissue, which plays an important part in the progression of renal disease.
Similar to atherosclerosis and NASH, intracellular lipid accumulation is governed by a balance between the infl ux, syntheses, and oxidation or effl ux of FAs and cholesterol. from other human diabetic kidney gene expression profi ling ( 31, 32, 40 ) and also described in human fi brotic liver as a result of NASH ( 42 ) . Angptl4 is an inhibitor of LPL and expressed in the podocyte. Angptl4 secreted by the podocyte to the circulation was recently suggested as a mechanism of hypertriglyceridemia in nephrotic syndrome ( 35 ) . We found upregulation of Angptl4 in DN kidneys that could contribute to serum hypertryglyceridemia, as well as LPL inhibition ( Fig. 4 ) .
The mechanism of lipotoxicity directly or indirectly involved activation of infl ammatory and profi brotic responses. We found a correlation between patient's eGFR and expression of lipid metabolic genes and infl ammatory cytokines TNF ␣ ( Figs. 1, 6 ; Tables 2, 3 ). Infl amation plays a central role in the progression of DN ( Fig. 1 ) and induces marked changes in lipid and lipoprotein metabolism (46) (47) (48) (49) (50) in animal models that resemble the changes we found in human kidneys, suggesting a possible role for infl amation in causing altered lipid metabolism, even when the serum lipid profi le is well controlled ( Table 1 ) .
In summary, we showed evidence for lipid accumulation and lipotoxicity in human kidneys. Accumulation of TGs and cholesterol in human kidney in diabetes can result from a mismatch between enhanced lipid uptake versus decreased lipid oxidation versus decreased catabolism and decreased effl ux; these changes may result in alterations in lipid metabolism and lipid accumulation ( Fig. 7 ) . We showed signifi cant correlation between dysregulated lipid metabolism, infl ammation, podocyte dysfunction, fi brosis, and eGFR. Understanding the mechanisms of lipid accumulation in human kidney and possible lipotoxicity may serve as a target for specifi c therapies aimed to slow the progression of glomerulosclerosis in DN.
The authors sincerely thank Ruth Miller for her linguistic assistance and EM technician Amalia Getsztain-Bakshi from Rabin Medical Center. To clarify possible mechanisms of TG accumulation in the kidney, we examined the expression of enzymes that are key regulators of FA metabolism (SCD1) (19) (20) (21) , increased uptake (CD36), and decreased expression of enzymes of fat ␤ -oxidation (ACO and CPT1). The expressions of PPAR ␣ and PPAR ␦ and their downstream enzymes ACO and CPT1 were decreased and correlated with the decline in eGFR ( Fig. 6 ) . Taken together these alterations in lipid metabolism clarify possible mechanisms for intracellular TG accumulation in diabetic kidneys.
To clarify mechanisms of cholesterol accumulation in the kidney, we examined genes that are master regulators of cholesterol synthesis, cholesterol effl ux, and cholesterol uptake (different lipoprotein receptors). We found upregulation in most lipoprotein receptors: LOX-1 (OLR-1), LDLR, acLDL scavenger receptor SR-A1, and CD36 ( Fig. 5 ) . These receptors were negatively correlated with eGFR. CCL16, the main cholesterol receptor in podocytes, was downregulated, possibly secondary to podocytopathy. There was marked downregulation of cholesterol effl ux genes, the ATP-binding cassette transporters (ABCA1, ABCG1) and apoE that also correlated with eGFR. Taken together, these alterations in cholesterol metabolism gene expression that can mediate increased cholesterol infl ux and impaired cholesterol effl ux may suggest possible mechanisms for intracellular cholesterol accumulation in the diabetic kidney.
Expression of mRNA of SREBP-1c, SREBP-2, and ChREBP and their target lipogenesis enzymes was downregulated in human DN, unlike the fi ndings in rodent models ( 39 ) , where only early manifestations of DN occur ( 45 ) . Changes that we observed in the diabetic human kidney did not always parallel data from animal models; these differences could be due to the fact that changes seen in the human kidney represent much prolonged exposure to the diabetic environment, but it is still possible that in the early stage of hyperglycemia there is increased denovo lipogenesis in the kidney. Our fi ndings parallel data processed
